1. Boyce, A.M., Chong, W.H., Yao, J., Gafni, R.I., Kelly, M.H., Chamberlain, C.E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J.Z., Farley, F.A., Molinolo, A.A., Bhattacharyya, N. & Collins, M.T. (2012) Denosumab treatment for fibrous dysplasia. J. Bone Miner. Res., 27, 1462-1470.
2. Branstetter, D., Rohrbach, K., Huang, L.Y., Soriano, R., Tometsko, M., Blake, M., Jacob, A.P. & Dougall, W.C. (2015) RANK and RANK ligand expression in primary human osteosarcoma. J. Bone Oncol., 4, 59-68.
3. Cohen, R.B., Hahn, G.V., Tabas, J.A., Peeper, J., Levitz, C.L., Sando, A., Sando, N., Zasloff, M. & Kaplan, F.S. (1993) The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J. Bone Joint Surg. Am., 75, 215-219.
4. Davenport, C., Harper, E., Forde, H., Rochfort, K.D., Murphy, R.P., Smith, D. & Cummins, P.M. (2016) RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release. Int. J. Biochem. Cell Biol., 77, 171-180.
5. Feinblatt, J.S., Berend, K.R. & Lombardi, A.V. Jr. (2005) Severe symptomatic heterotopic ossification and dislocation: a complication after two-incision minimally invasive total hip arthroplasty. J. Arthroplasty, 20, 802-806.